Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial
Musazadeh V, Dehghan P, Khoshbaten M
Published in European Journal of Gastroenterology & Hepatology
Methodology
Triple-blind placebo-controlled randomized trial in 46 NAFLD patients assigned to camelina sativa oil or placebo for 12 weeks alongside a weight-loss diet; liver enzymes, adiponectin, lipid profile, atherogenic index and anthropometry assessed.
Key Findings
Significant improvements versus placebo in weight, BMI, waist circumference, waist-to-hip ratio, triglycerides, total and LDL cholesterol, atherogenic index, ALT and adiponectin; HDL-c and several other measures were unchanged.
Conclusions
Camelina oil improved metabolic and hepatic markers in NAFLD during a weight-loss program.
Limitations
Small single-centre sample, overlapping cohort with related trials, no imaging or biopsy endpoint, short duration.
Supplements Studied
CSO caused significant differences in weight, BMI, waist circumference, waist-to-hip ratio, triglyceride, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c) ... in the CSO group compared with the placebo group (P < 0.046 for all).
Outcomes Measured
CSO caused significant differences in ... alanine aminotransferase, and adiponectin concentrations in the CSO group compared with the placebo group.
CSO caused significant differences in weight, BMI, waist circumference, waist-to-hip ratio, triglyceride ... compared with the placebo group.
CSO caused significant differences in ... triglyceride, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), TC/HDL-c, LDL-c/HDL-c, atherogenic index.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Tabriz University of Medical Sciences
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.